Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
4.8
%Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales3,104,064¥ millionYear on year +4.8%Progress 98.7%
Operating profit36,164¥ millionYear on year -5.0%Progress 106.7%
Ordinary income38,634¥ millionYear on year -4.6%Progress 105.6%
Net income attributable to owners of the parent41,746¥ millionYear on year +52.4%Progress 200.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥229.64
Operating Margin1.2 %
Financial position at period-end
Total assets1,507,016¥ million
of which net assets 507,903 ¥ millionEquity ratio 33.7%vs. prior year-end +0.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+38,566
Investment-8,721
Financials-14,047
Net change+15,798
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥190,684 million
Segment revenue
Wholesale business for prescription pharmaceuticals and other products2,782,58488.6%
Self-medication products wholesale business267,0748.5%
Pharmaceuticals and other products manufacturing business52,1791.7%
Dispensing pharmacy and other businesses37,1741.2%
Segment profit
Wholesale business for prescription pharmaceuticals and other products33,29787.6%
Self-medication products wholesale business3,0127.9%
Pharmaceuticals and other products manufacturing business1,2033.2%
Dispensing pharmacy and other businesses4991.3%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥3,144,000 million (YoY +1.3%)
Operating profit¥33,900 million (YoY -6.3%)
Ordinary income¥36,600 million (YoY -5.3%)
Net income¥20,800 million (YoY -50.2%)
Annual Dividend Forecast¥63 → ¥71（+12.7%）
Payout ratioActual results for the current fiscal year 29.6 % / Next-year forecast 61 %
Factors Behind Changes in Business Performance
Revenue growth resulting from the promotion of the Neo-Primary strategy and increased handling of products with restricted distribution, including specialty pharmaceuticals; the impact on profit of drug price revisions, higher logistics costs and business investment costs; and the recognition of gains on sales of investment securities resulting from the reduction of cross-shareholdings.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 4 / Company name セルリソーシズ株式会社, 株式会社ミヤノメディックス, 東日本メディカルシステム株式会社, 株式会社テクノ・スズタ / Excluded Number of companies 0 / Company name Not disclosed / Material changes No
Material subsequent eventsAt a meeting of the Board of Directors held on 15 May 2026, the company resolved to repurchase treasury shares. The number of shares to be acquired is up to 6,307,800, and the total acquisition price is up to ¥15,000 million. The purpose is to improve capital efficiency and enhance shareholder returns.
Impairment loss¥290 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥12 million, Gain on sale of investment securities ¥25,331 million, Total extraordinary income ¥25,343 million / Extraordinary loss Loss on sale of fixed assets ¥78 million, Loss on Disposal of Fixed Assets ¥294 million, Impairment Losses ¥290 million, Loss on sale of investment securities ¥4 million, Impairment Loss on Investment Securities ¥1,267 million, Loss on valuation of investments ¥35 million, Total extraordinary loss ¥1,970 million
Depreciation and amortization¥14,647 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End191,300,000 Shares
Treasury Shares at Period-End9,582,018 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥3,104,064 million (YoY +4.8%) |
| Operating profit | ¥36,164 million (YoY -5.0%) |
| Ordinary income | ¥38,634 million (YoY -4.6%) |
| Profit attributable to owners of the parent | ¥41,746 million (YoY +52.4%) |
| Net income per share | ¥229.64 |
| Operating Margin | 1.2 % |
| Equity ratio | End of the current fiscal period 33.7 / End of previous period 33.5 |
| Total assets | ¥1,507,016 million |
| Net assets | ¥507,903 million |
| Cash flows from operating activities | ¥38,566 million |
| Cash flows from investing activities | ¥-8,721 million |
| Cash flows from financing activities | ¥-14,047 million |
| Cash and cash equivalents at end of period | ¥190,684 million |
| Full-year earnings forecast | Net Sales ¥3,144,000 million (YoY +1.3%) / Operating profit ¥33,900 million (YoY -6.3%) / Ordinary income ¥36,600 million (YoY -5.3%) / Net income ¥20,800 million (YoY -50.2%) |
| Annual Dividend Forecast | ¥63 → ¥71（+12.7%） |
| Payout ratio | Actual results for the current fiscal year 29.6 % / Next-year forecast 61 % |
| Segment revenue | Segment Wholesale business for prescription pharmaceuticals and other products / Net Sales ¥2,782,584 million / yoy_pct ¥5.4 million, Segment Self-medication products wholesale business / Net Sales ¥267,074 million / yoy_pct ¥0.5 million, Segment Pharmaceuticals and other products manufacturing business / Net Sales ¥52,179 million / yoy_pct ¥-3.5 million, Segment Dispensing pharmacy and other businesses / Net Sales ¥37,174 million / yoy_pct ¥0.4 million |
| Segment profit | Segment Wholesale business for prescription pharmaceuticals and other products / Segment profit ¥33,297 million / yoy_pct ¥0.7 million, Segment Self-medication products wholesale business / Segment profit ¥3,012 million / yoy_pct ¥2.1 million, Segment Pharmaceuticals and other products manufacturing business / Segment profit ¥1,203 million / yoy_pct ¥-7.1 million, Segment Dispensing pharmacy and other businesses / Segment profit ¥499 million / yoy_pct ¥-16.3 million |
| Depreciation and amortization | ¥14,647 million |
| Impairment loss | ¥290 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥12 million, Gain on sale of investment securities ¥25,331 million, Total extraordinary income ¥25,343 million / Extraordinary loss Loss on sale of fixed assets ¥78 million, Loss on Disposal of Fixed Assets ¥294 million, Impairment Losses ¥290 million, Loss on sale of investment securities ¥4 million, Impairment Loss on Investment Securities ¥1,267 million, Loss on valuation of investments ¥35 million, Total extraordinary loss ¥1,970 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 4 / Company name セルリソーシズ株式会社, 株式会社ミヤノメディックス, 東日本メディカルシステム株式会社, 株式会社テクノ・スズタ / Excluded Number of companies 0 / Company name Not disclosed / Material changes No |
| Material subsequent events | At a meeting of the Board of Directors held on 15 May 2026, the company resolved to repurchase treasury shares. The number of shares to be acquired is up to 6,307,800, and the total acquisition price is up to ¥15,000 million. The purpose is to improve capital efficiency and enhance shareholder returns. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 191,300,000 Shares |
| Treasury Shares at Period-End | 9,582,018 Shares |
| Factors Behind Changes in Business Performance | Revenue growth resulting from the promotion of the Neo-Primary strategy and increased handling of products with restricted distribution, including specialty pharmaceuticals; the impact on profit of drug price revisions, higher logistics costs and business investment costs; and the recognition of gains on sales of investment securities resulting from the reduction of cross-shareholdings. |
Items this document does not state (4)
Revision to Earnings ForecastShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the wholesale business for prescription pharmaceuticals and other products, revenue increased as a result of promoting the Neo-Primary strategy and handling more products with restricted distribution, including specialty pharmaceuticals. However, drug price revisions, higher logistics costs including personnel expenses, and business investment costs weighed on profit. Net income increased due to the recognition of ¥25.331 billion in gains on sales of investment securities resulting from the reduction of cross-shareholdings. For the next fiscal year, the company expects low market growth and higher logistics costs, taking into account the risk associated with the U.S. Most Favored Nation (MFN) drug pricing policy.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.